Novartis wins an early approval for a new skin cancer drug

Damian Garde Novartis won accelerated approval for a promising oncology drug, gearing up to launch a new treatment for an advanced form of the most common type of skin cancer. FierceBiotech ...

UPDATED: Celgene chief Bob Hugin isn’t done betting on ‘binary’ biotech deals

John Carroll By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the ...

FDA scales up CV warnings on NSAIDs

Carly Helfand The FDA already had a warning out about the cardiovascular safety of nonsteroidal anti-inflammatory drugs, or NSAIDs. But on Thursday, it strengthened that warning for ...

Novartis’ pay-for-performance Entresto plan has its critics–Express Scripts’ Miller among them

Carly Helfand Novartis has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the ...

Intercept files its ‘breakthrough’ liver drug for rare disease approval

Damian Garde Intercept Pharmaceuticals has submitted its top candidate to the FDA for approval in primary biliary cirrhosis, a rare disease that results in serious liver damage. FierceBiotech ...

How well paid are pharma execs? Best in healthcare, survey shows

Tracy Staton How does pharma executive pay compare with the rest of healthcare? Forbes columnist Dan Munro decided to find out–and the answer is that drugmakers pay their top ...

Roche’s $100M Alzheimer’s study could shift the balance in R&D

Damian Garde Despite all the excitement over Biogen's recent Phase I success in Alzheimer's, the question of whether attacking protein buildups in the brain can in fact treat ...

Galapagos’ closely watched rheumatoid arthritis drug filgotinib scores in PhIIb

John Carroll Belgium's Galapagos says that its oral JAK1 inhibitor filgotinib met its primary and other endpoints in a crucial Phase IIb study for rheumatoid arthritis. FierceBiotech ...

CEO Dekkers’ legacy at Bayer? Embracing risk, à la its American rivals

Carly Helfand Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But ...

Merck bets big on NGM with a $450M handshake

Damian Garde Taking a page from famed partners like Sanofi and Regeneron and Roche and Genentech, Merck has signed a sweeping R&D deal with biotech NGM Biopharmaceuticals, promising ...

Bayer feels sting of mixed decision from NICE for Eylea’s use in diabetics

Emily Wasserman Bayer has won an approval from England's National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The ...

Ex-Merck analyst pleads guilty to insider trading

Eric Palmer Former Merck analyst Zachary Zwerko pleaded guilty to federal insider-trading charges on Thursday for passing merger tips to a business school chum. The tips allowed the ...
Page 5 of 41« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS